At 24 months, endocrine therapy appeared to have a more negative effect on HRQOL as measured by the global health status (GHS ...

A machine learning (ML) model incorporating both clinical and genomic factors outperformed models based solely on either clinical or genomic data in predicting which patients with hormone receptor (HR ...

The ZEST clinical trial, designed to evaluate niraparib (Zejula) for the prevention of breast cancer recurrence in patients with circulating tumor DNA (ctDNA), failed to accrue enough patients ...

Bonus Jun 12, 2000 Jun 28, 2000 May 25, 2000 Bonus Ratio: 1 share(s) for every 1 shares held Bonus--Jul 25, 1977 Bonus Ratio: 4 share(s) for every 5 shares held Bonus--Jul 25, 1972 Bonus Ratio: 2 ...

Researchers presented data from trials of HER2-targeted therapies from Jiangsu Hengrui Medicine, Jazz Pharma, Roche, and RemeGen.